Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia
NCT ID: NCT00174330
Last Updated: 2021-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
330 participants
INTERVENTIONAL
2005-05-31
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
NCT00143234
A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin
NCT00530946
Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.
NCT00174304
Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia
NCT00330785
The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.
NCT00656331
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
atorvastatin
amlodipine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects with other atherosclerotic disease.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Beijing, Beijing Municipality, China
Pfizer Investigational Site
Guangzhou, Guangdong, China
Pfizer Investigational Site
Guangzhou, Guangdong, China
Pfizer Investigational Site
Guangzhou, Guangdong, China
Pfizer Investigational Site
Nanjing, Jiangsu, China
Pfizer Investigational Site
Shenyang, Liaoning, China
Pfizer Investigational Site
Shanghai, Shanghai Municipality, China
Pfizer Investigational Site
Hangzhou, Zhejiang, China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Tianjin, , China
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3841026
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.